platelets maximum specific binding of J-125-IGF-1 was 1.6% with a n unspec . binding of 0.3%. 1/2 max. binding was shown at 2 0 ng/ml IGF-1,the affinity constant was 0 . 6 7~1 0 (Y)xM(-1). IGF-1 internalisation experiments were performed by preincubation with J-125-IGF -1 and dissociation of labeled hormone after cell placement into IGF-1 free medium o r displacement by inactive IGF-1.Increasingly incomplete dissociation of J125-IGF-1 was demonstrated for preincubation times > lh. These results are confirmed by diminished displacement of cell-bound J-125-IGF-1 by unlabeled hormone after a preincubation period of >lh.Preliminary results indicate that lysed platelets contain remarkable amounts of IGF-1. -I t has to be considered that platelets' serve as a reservoir from which IGF-1,following a local injury,is released after aggregation,and together with PDGF might stimulate fibroblast growth i n wound healing.
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University Children's Hospital, Tiibingen, Federal Republic of Germany SOMATOMEDIXS POTEXTIATE IXTERLEUKIX 2 IXDUCED STIMULA'PIOX OF XATURAL KILLER CELL ACTIVITY Xatural killer (NK) activity of peripheral blood lymphocytes (PBL) is reduced in GHD. We, therefore, investigated whether or not IGF-I and IGF-I1 have any influence on XK activity in the presence or absence of interleukin 2 (IL-2). PBL were obtained by fractionation of blood cells on a Ficoll gradient. After incubation in RPMI 1640 medium with or without IL-2 (100 Ulml), IGF-I and/or IGF-I1 (25 nglml) for 15 h cytotoxicity was measured by a 4-h 51-Cr-release assay utilizing the cell line K562. IGF-I and IGF-I1 alone or in combination had no effect on XK activity. The stimulatory effect of IL-2 (100%) was not significantly enhanced by further addition of IGF-I ( 123 ? 48%) or IGF-I1 (118 T 36%). if inter-individual means (?=I 1) were regarded, although in some individuals a significant potentiation (p<0.001) was observed (maximal values with ICF-I: 232%. . In contrast, addition of both ICF-I and -11 potentiated the IL-2 effect significantly (p<0.001) even if the inter-individual mean was regarded (146 t25X). In 7 out of I 1 individuals the combined effect of IGF-I and -11 was clearly more than additive. Dose-response curves of IGF-I and -11 in the presence of IL-2 exhibited a significant increase of XK activity between 0.1 and 1 0 nglml. It is concluded that (1) somatomedins are modulators of XK cell function and (2) that IGF-I and -11 may act synergistically in particular systems.
.. In thc present pilot study it was found that 1 2 5~-~~~-~ receptor binding docs not correlate with extreme short or tall heights as docs scrum GF 1 and CtI-BP. Thc ability of ICF-1 to stimulate
-.
uptakc of ( ti) amlno-iso-butyric acid (AIB) by fibroblasts of the same paticnts is being perCormed. 
PLASMA INSULIN-LIKE GROWTH FACTOR (1GF)-I AND I1 LNELS AND BIOASSAYABLE SOMATOMEDIN ACTIVITY IN CHILDREN WITH CEREBRAL GIGANTISM (SOTOS SYNDROME).
Cerebral gigantism (Sotos syndrome) is characterized by a large birth size, excessive statural growth, advanced bone age, mental retardation and dysmorphic features. In this study 30 plasma samples of 14 children with Sotos syndrome were assayed for IGF-I and I1 and bioassayable somatomedin activity (SM-act). Immunoreactive IGF-I was determined in unextracted plasma and compared to the Nichols Institute references. Immunoreactive IGF-I1 was measured with a nonequilibrium RIA, using the tyrosylated eight amino acid C-peptide region of IGF-I1 (CP-11) and an antiserum against this fragment (kindly donated by Dr. R. Hintz). SM-act was determined with the porcine cartilage bioassay. All but 3 values of IGF-I were within the + 2 SD range for age. When the data were expressed as a Z-score for age, mean IGF-I decreased from -0.1 (range -1.0 to t1.0, n=6) at 0-3 years to -1.1 (range -2.0 to 0.3, n=7) at 3-5 years. IGF-I1 levels were generally within the reference range. SM-act was usually low between 1 and 5 years of age (mean -2.2 SD. range -5.0 to 3.6, n=ll) and in the lower normal range thereafter. These IGF-I and SM-act results are in contrast to the data in constitutional tall stature. The relatively low somatomedin levels between 1 and 5 years of age concur with the deceleration of growth which is usually seen after the first year of life in children with Sotos syndrome. 
12 BlOACTlVlTY O F T H E IGF-I BINDING SUB-UNIT O F T H E
The biological activity of the partially purified insulin-like growth factor 1 [IGF-I1 binding protein [BPI of the large MW circulating complex (1115 K1 in human plasma was evaluated using our IGF-I Leydig [LC cell bioassay model that specifically differenciates under IGF-I action [Bernier J. Cell.Physiol. 129:257.19861 . This B P inhibits both the 125-IG-1 binding to the specific L C IGF type 1 receptors and the dramatic increase in testosterone secretion [in response to LHI specifically induced by IGF-I. BP also inhibits the IGF-I dependent increment in L H -H C G receptor number. These BP inhibitions of IGF-I actions are specific end dose dependent. These data help to further understand the nature of the circulating IGF-I large MW complex and function of its IGF-I BP. Partial purification of the IGF-I B P subunit included emonium sulfate precipitation. O E A E sephndex A50.S-300 sephacryl [pH-3.51 and IGF-I affinity chromatogrephies then C 4 reverse phase HPLC. O n SDS-PAGE. O E A E peak 2 [containing B P ) cross-linked to 125-IGF-1 lead to two specific bands (39 K and 211 K1. This material gel filtrated 15-300. pH-7.41 lead to a 54 K complex. When cross-linking included 125-IGF-I. O E A E peak 2 end 3. SDS-PAGE lead to a major 911 K. a minor 39 K and a constant 24 K band. 5-200 gel filtration then recovered a large IGF-I MW complex. but of 125 K
